Recent FDA approvals and therapies under FDA review are adding new treatments to the armamentarium, said Paul Hahn, MD, vitreoretinal surgeon at NJRetina. Patients with uveitis and their physicians ...
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of ...
Podium presentation on the pharmacokinetics and safety of OPT-302 in retinal vascular diseases Participation in “Live From ASRS” virtual KOL discussion on market trends and new treatments in wet AMD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results